M. K. AKBOĞA Et Al. , "Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?," ANGIOLOGY , vol.71, no.5, pp.479-480, 2020
AKBOĞA, M. K. Et Al. 2020. Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?. ANGIOLOGY , vol.71, no.5 , 479-480.
AKBOĞA, M. K., Okutucu, S., Sabanoglu, C., Yayla, C., Ertem, A. G., & Efe, T. H., (2020). Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?. ANGIOLOGY , vol.71, no.5, 479-480.
AKBOĞA, MEHMET Et Al. "Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?," ANGIOLOGY , vol.71, no.5, 479-480, 2020
AKBOĞA, MEHMET K. Et Al. "Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?." ANGIOLOGY , vol.71, no.5, pp.479-480, 2020
AKBOĞA, M. K. Et Al. (2020) . "Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?." ANGIOLOGY , vol.71, no.5, pp.479-480.
@article{article, author={MEHMET KADRİ AKBOĞA Et Al. }, title={Are Endocan and Ischemia-Modified Albumin Reliable Biomarkers for Endothelial Dysfunction in Type 2 Diabetes Mellitus?}, journal={ANGIOLOGY}, year=2020, pages={479-480} }